PMID- 23106890
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20131121
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 21
DP  - 2012 Nov
TI  - A multi-center, double-blind, randomized, parallel group study to evaluate the 
      effects of two different doses of losartan on morbidity and mortality in Chinese 
      patients with symptomatic heart failure intolerant of angiotensin converting 
      enzyme inhibitor treatment.
PG  - 3868-74
AB  - BACKGROUND: There have been no mortality/morbidity endpoint studies with losartan 
      in Chinese heart failure patients. The objective was to evaluate the effects of 
      high-dose vs. low-dose losartan on clinical outcomes in Chinese subjects with 
      heart failure. METHODS: This study was a post hoc analysis of the Heart failure 
      Endpoint evaluation of Angiotensin II Antagonist losartan (HEAAL) trial (n = 
      545). Chinese adults with symptomatic heart failure (New York Heart Association 
      (NYHA) II-IV) intolerant of treatment with angiotensin converting enzyme (ACE) 
      inhibitors were randomized to losartan 150 mg or 50 mg daily. The primary 
      endpoint was the composite event rate of all-cause death or hospitalization for 
      heart failure. Safety and tolerability were assessed. RESULTS: Median follow-up 
      was 4.8 years. Baseline characteristics were generally similar to the overall 
      HEAAL cohort. Overall, 120 (44.1%) subjects in the losartan 150 mg group and 137 
      (50.2%) subjects in the losartan 50 mg group died (any cause) or were 
      hospitalized for heart failure (hazard ratio (OR) 0.807, 95%CI 0.631 - 1.031). 
      There were no notable differences between treatment groups in the proportion of 
      subjects with adverse experiences. CONCLUSION: The results of this post hoc 
      analysis in Chinese subjects, although not powered to show significance, were 
      generally consistent with the main study results, which demonstrated a 
      significantly reduced risk of all cause death or hospitalization for heart 
      failure with daily losartan 150 mg vs. losartan 50 mg in subjects with 
      symptomatic heart failure and intolerance to ACE inhibitors, supporting the use 
      of the higher dose for optimum clinical benefit.
FAU - Hu, Da-Yi
AU  - Hu DY
AD  - Department of Cardiology, Peking University People's Hospital, Beijing 100044, 
      China.
FAU - Huang, Jun
AU  - Huang J
FAU - Cai, Nai-Sheng
AU  - Cai NS
FAU - Zhu, Wen-Ling
AU  - Zhu WL
FAU - Li, Yi-Shi
AU  - Li YS
FAU - Massaad, Rachid
AU  - Massaad R
FAU - Hanson, Mary E
AU  - Hanson ME
FAU - Dickstein, Kenneth
AU  - Dickstein K
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Losartan/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
EDAT- 2012/10/31 06:00
MHDA- 2013/11/20 06:00
CRDT- 2012/10/31 06:00
PHST- 2012/10/31 06:00 [entrez]
PHST- 2012/10/31 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Nov;125(21):3868-74.